PHYTOCHEMICAL AND PHARMACOLOGICAL SCREENING OF CROCUS SATIVUS FOR ITS POTENTIAL IN EXPERIMENTAL INDUCED NEUROPATHIC PAIN IN RAT

Cisplatin is a widely used anticancer drug; however, its clinical application is often associated with peripheral neuropathy, which is characterised by impaired motor coordination, altered sensory responses, oxidative stress and inflammation. The present study was designed to evaluate the potential neuroprotective activity of the hydroalcoholic extract of Crocus sativus against cisplatin-induced neuropathy in experimental animals. The powdered plant material was subjected to physicochemical evaluation, followed by hydroalcoholic extraction and phytochemical screening. The percentage yield of the extract was found to be 4.28% w/w. Phytochemical screening revealed the presence of alkaloids, flavonoids, phenols, carbohydrates, saponins and tannins. The total flavonoid and total phenolic contents were estimated to be 0.685 and 0.719 mg/100 mg of dried extract, respectively. The neuroprotective potential was evaluated by assessing behavioural parameters, including rota-rod retention time, cold allodynia response and hot plate latency. Oxidative stress markers, including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH) and catalase (CAT), were also investigated, along with the inflammatory marker tumour necrosis factor-alpha (TNF-α).

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24366437
Primary Topic
Saffron Plant Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PHYTOCHEMICAL AND PHARMACOLOGICAL SCREENING OF CROCUS SATIVUS FOR ITS POTENTIAL IN EXPERIMENTAL INDUCED NEUROPATHIC PAIN IN RAT

Rakesh Kumar Gawaly, Udit Narain Soni, Mirza Muhammad Abdul Rehman Baig
Zenodo (CERN European Organization for Nuclear Research)
Saffron Plant Research Studies
article

PHYTOCHEMICAL AND PHARMACOLOGICAL SCREENING OF CROCUS SATIVUS FOR ITS POTENTIAL IN EXPERIMENTAL INDUCED NEUROPATHIC PAIN IN RAT

Rakesh Kumar Gawaly, Udit Narain Soni, Mirza Muhammad Abdul Rehman Baig
article en

Abstract

Cisplatin is a widely used anticancer drug; however, its clinical application is often associated with peripheral neuropathy, which is characterised by impaired motor coordination, altered sensory responses, oxidative stress and inflammation. The present study was designed to evaluate the potential neuroprotective activity of the hydroalcoholic extract of Crocus sativus against cisplatin-induced neuropathy in experimental animals. The powdered plant material was subjected to physicochemical evaluation, followed by hydroalcoholic extraction and phytochemical screening. The percentage yield of the extract was found to be 4.28% w/w. Phytochemical screening revealed the presence of alkaloids, flavonoids, phenols, carbohydrates, saponins and tannins. The total flavonoid and total phenolic contents were estimated to be 0.685 and 0.719 mg/100 mg of dried extract, respectively. The neuroprotective potential was evaluated by assessing behavioural parameters, including rota-rod retention time, cold allodynia response and hot plate latency. Oxidative stress markers, including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH) and catalase (CAT), were also investigated, along with the inflammatory marker tumour necrosis factor-alpha (TNF-α).

Zenodo (CERN European Organization for Nuclear Research)
Saffron Plant Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon